English

REGENXBIO Inc.

EDGAR

RGNX Current report (8-K) · filed 2026-10-16

Annual consolidated revenue for 2025: about USD 170.4M, using the latest reported figures. The previous period, 2024, was about USD 83.33M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

108 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 108019000 USD Source

Operating margin

27.09%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 29263000 USD Source
Revenue: 108019000 USD Source

Operating cash flow

-62.2 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -138424000 USD Source
Operating Cash Flow: -76186000 USD Source

Free cash flow

-63 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -138424000 USD Source
Operating Cash Flow: -76186000 USD Source
Capital Expenditure: 1995000 USD Source
Capital Expenditure: 1235000 USD Source

Cash and cash equivalents: 36.5 million USD 2026-06-30 Source
Exact value

36487000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 54.2 million shares 2026-06-30 Source
Exact value

54164000 shares

Reported share-count change

7.49% · 3.78 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

50389000 shares · 2025-06-30· Source
54164000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

174 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 29733000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 170441000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 140104000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 6393000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 108019000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-196 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -61941000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -193878000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -126729000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -90051000 USD · 2026-01-01 – 2026-03-31 Source
Net income: 22709000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-247 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -71673000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15713000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -123963000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -71673000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -76186000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -138424000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -76186000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

2.99 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 1906000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1415000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2414000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1906000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1235000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1995000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1235000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-250 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -71673000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15713000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -123963000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -71673000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -76186000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -138424000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -76186000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1906000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1415000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2414000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1906000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1235000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1995000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1235000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-16.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+104.5%

Prior period

USD 83.33 million

2024-01-01 – 2024-12-31
Current period

USD 170.44 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

170441000 − 83328000 = 87113000 USD

83328000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
170441000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Year-over-year change in Revenue: 87113000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 170441000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#1750521 Filing: 000119312526094013 Input fundies:Revenue: 83328000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#1752166 Filing: 000119312526094013
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 33.22 million

Prior period

−USD 227.1 million

2024-01-01 – 2024-12-31
Current period

−USD 193.88 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-193878000 − -227102000 = 33224000 USD

-227102000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-193878000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Year-over-year change in Net income: 33224000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -193878000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#4136082 Filing: 000119312526094013 Input fundies:NetIncome: -227102000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#4137940 Filing: 000119312526094013
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 49.16 million

Prior period

−USD 173.13 million

2024-01-01 – 2024-12-31
Current period

−USD 123.96 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-123963000 − -173125000 = 49162000 USD

-173125000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-123963000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Year-over-year change in Operating cash flow: 49162000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -123963000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2140516 Filing: 000119312526094013 Input fundies:OperatingCashFlow: -173125000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2142296 Filing: 000119312526094013
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-0.9%

Prior period

USD 2.44 million

2024-01-01 – 2024-12-31
Current period

USD 2.41 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2414000 − 2436000 = -22000 USD

2436000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2414000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Year-over-year change in Capital expenditure: -22000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2414000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2158719 Filing: 000119312526094013 Input fundies:CapitalExpenditure: 2436000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2160592 Filing: 000119312526094013
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 170.44 million 100% of revenue
Operating costs Derived USD 331.64 million 195% of revenue
Operating income −USD 161.2 million −95% of revenue
Tax, interest and other Derived USD 32.68 million 19% of revenue
Net income −USD 193.88 million −114% of revenue

Cash

Operating cash flow −USD 123.96 million −73% of revenue
Capital expenditure USD 2.41 million 1.4% of revenue
Free cash flow Derived −USD 126.38 million −74% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,524% of revenue.
2017 Operating loss: operating costs were 830% of revenue.
2018 Net income was higher than operating income, so the split is not drawn.
2019 Operating loss: operating costs were 523% of revenue.
2020 Operating loss: operating costs were 177% of revenue.
2021 27%66%
2022 Operating loss: operating costs were 333% of revenue.
2023 Operating loss: operating costs were 397% of revenue.
2024 Operating loss: operating costs were 380% of revenue.
2025 Operating loss: operating costs were 195% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	4589000	69929000 Derived	-65340000	-2373000 Derived	-62967000	-56707000 Derived	Source 2016-01-01 – 2016-12-31: 4589000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -65340000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -62967000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -48558000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 8149000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	10393000	86278000 Derived	-75885000	-2716000 Derived	-73169000	-65152000 Derived	Source 2017-01-01 – 2017-12-31: 10393000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -75885000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -73169000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -57992000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 7160000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	218505000	130405000 Derived	88100000	-11837000 Derived	99937000	91370000 Derived	Source 2018-01-01 – 2018-12-31: 218505000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 88100000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 99937000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 104648000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 13278000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	35233000	184231000 Derived	-148998000	-54265000 Derived	-94733000	-119425000 Derived	Source 2019-01-01 – 2019-12-31: 35233000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -148998000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -94733000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -107705000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 11720000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	154567000	273800000 Derived	-119233000	-7983000 Derived	-111250000	-80930000 Derived	Source 2020-01-01 – 2020-12-31: 154567000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -119233000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -111250000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -54061000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 26869000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	470347000	310367000 Derived	159980000	32140000 Derived	127840000	134700000 Derived	Source 2021-01-01 – 2021-12-31: 470347000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 159980000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 127840000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 218875000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 84175000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	112724000	375600000 Derived	-262876000	17445000 Derived	-280321000	-238212000 Derived	Source 2022-01-01 – 2022-12-31: 112724000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -262876000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -280321000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -207488000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 30724000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	90242000	358370000 Derived	-268128000	-4634000 Derived	-263494000	-228367000 Derived	Source 2023-01-01 – 2023-12-31: 90242000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -268128000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -263494000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -218407000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 9960000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	83328000	316674000 Derived	-233346000	-6244000 Derived	-227102000	-175561000 Derived	Source 2024-01-01 – 2024-12-31: 83328000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -233346000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -227102000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -173125000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 2436000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	170441000	331639000 Derived	-161198000	32680000 Derived	-193878000	-126377000 Derived	Source 2025-01-01 – 2025-12-31: 170441000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -161198000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -193878000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -123963000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2414000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 170.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	4589000	Revenue: 4589000 Open source
20172017-12-31	Revenue	10393000	Revenue: 10393000 Open source
20182018-12-31	Revenue	218505000	Revenue: 218505000 Open source
20192019-12-31	Revenue	35233000	Revenue: 35233000 Open source
20202020-12-31	Revenue	154567000	Revenue: 154567000 Open source
20212021-12-31	Revenue	470347000	Revenue: 470347000 Open source
20222022-12-31	Revenue	112724000	Revenue: 112724000 Open source
20232023-12-31	Revenue	90242000	Revenue: 90242000 Open source
20242024-12-31	Revenue	83328000	Revenue: 83328000 Open source
20252025-12-31	Revenue	170441000	Revenue: 170441000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

104.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-39.5%	Revenue: 4589000 Open source Revenue: 7588000 Open source
20172017-12-31	Year over year	126.5%	Revenue: 10393000 Open source Revenue: 4589000 Open source
20182018-12-31	Year over year	2,002.4%	Revenue: 218505000 Open source Revenue: 10393000 Open source
20192019-12-31	Year over year	-83.9%	Revenue: 35233000 Open source Revenue: 218505000 Open source
20202020-12-31	Year over year	338.7%	Revenue: 154567000 Open source Revenue: 35233000 Open source
20212021-12-31	Year over year	204.3%	Revenue: 470347000 Open source Revenue: 154567000 Open source
20222022-12-31	Year over year	-76%	Revenue: 112724000 Open source Revenue: 470347000 Open source
20232023-12-31	Year over year	-19.9%	Revenue: 90242000 Open source Revenue: 112724000 Open source
20242024-12-31	Year over year	-7.7%	Revenue: 83328000 Open source Revenue: 90242000 Open source
20252025-12-31	Year over year	104.5%	Revenue: 170441000 Open source Revenue: 83328000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -94.6% 2025

Net margin -113.8% 2025

Free cash flow margin -74.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-1,423.8%	Operating Income: -65340000 Open source Revenue: 4589000 Open source
20172017-12-31	Operating margin	-730.2%	Operating Income: -75885000 Open source Revenue: 10393000 Open source
20182018-12-31	Operating margin	40.3%	Operating Income: 88100000 Open source Revenue: 218505000 Open source
20192019-12-31	Operating margin	-422.9%	Operating Income: -148998000 Open source Revenue: 35233000 Open source
20202020-12-31	Operating margin	-77.1%	Operating Income: -119233000 Open source Revenue: 154567000 Open source
20212021-12-31	Operating margin	34%	Operating Income: 159980000 Open source Revenue: 470347000 Open source
20222022-12-31	Operating margin	-233.2%	Operating Income: -262876000 Open source Revenue: 112724000 Open source
20232023-12-31	Operating margin	-297.1%	Operating Income: -268128000 Open source Revenue: 90242000 Open source
20242024-12-31	Operating margin	-280%	Operating Income: -233346000 Open source Revenue: 83328000 Open source
20252025-12-31	Operating margin	-94.6%	Operating Income: -161198000 Open source Revenue: 170441000 Open source
20162016-12-31	Net margin	-1,372.1%	Net Income: -62967000 Open source Revenue: 4589000 Open source
20172017-12-31	Net margin	-704%	Net Income: -73169000 Open source Revenue: 10393000 Open source
20182018-12-31	Net margin	45.7%	Net Income: 99937000 Open source Revenue: 218505000 Open source
20192019-12-31	Net margin	-268.9%	Net Income: -94733000 Open source Revenue: 35233000 Open source
20202020-12-31	Net margin	-72%	Net Income: -111250000 Open source Revenue: 154567000 Open source
20212021-12-31	Net margin	27.2%	Net Income: 127840000 Open source Revenue: 470347000 Open source
20222022-12-31	Net margin	-248.7%	Net Income: -280321000 Open source Revenue: 112724000 Open source
20232023-12-31	Net margin	-292%	Net Income: -263494000 Open source Revenue: 90242000 Open source
20242024-12-31	Net margin	-272.5%	Net Income: -227102000 Open source Revenue: 83328000 Open source
20252025-12-31	Net margin	-113.8%	Net Income: -193878000 Open source Revenue: 170441000 Open source
20162016-12-31	Free cash flow margin	-1,235.7%	Revenue: 4589000 Open source Operating Cash Flow: -48558000 Open source Capital Expenditure: 8149000 Open source
20172017-12-31	Free cash flow margin	-626.9%	Revenue: 10393000 Open source Operating Cash Flow: -57992000 Open source Capital Expenditure: 7160000 Open source
20182018-12-31	Free cash flow margin	41.8%	Revenue: 218505000 Open source Operating Cash Flow: 104648000 Open source Capital Expenditure: 13278000 Open source
20192019-12-31	Free cash flow margin	-339%	Revenue: 35233000 Open source Operating Cash Flow: -107705000 Open source Capital Expenditure: 11720000 Open source
20202020-12-31	Free cash flow margin	-52.4%	Revenue: 154567000 Open source Operating Cash Flow: -54061000 Open source Capital Expenditure: 26869000 Open source
20212021-12-31	Free cash flow margin	28.6%	Revenue: 470347000 Open source Operating Cash Flow: 218875000 Open source Capital Expenditure: 84175000 Open source
20222022-12-31	Free cash flow margin	-211.3%	Revenue: 112724000 Open source Operating Cash Flow: -207488000 Open source Capital Expenditure: 30724000 Open source
20232023-12-31	Free cash flow margin	-253.1%	Revenue: 90242000 Open source Operating Cash Flow: -218407000 Open source Capital Expenditure: 9960000 Open source
20242024-12-31	Free cash flow margin	-210.7%	Revenue: 83328000 Open source Operating Cash Flow: -173125000 Open source Capital Expenditure: 2436000 Open source
20252025-12-31	Free cash flow margin	-74.1%	Revenue: 170441000 Open source Operating Cash Flow: -123963000 Open source Capital Expenditure: 2414000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -124M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-48558000	Operating Cash Flow: -48558000 Open source
20172017-12-31	Operating cash flow	-57992000	Operating Cash Flow: -57992000 Open source
20182018-12-31	Operating cash flow	104648000	Operating Cash Flow: 104648000 Open source
20192019-12-31	Operating cash flow	-107705000	Operating Cash Flow: -107705000 Open source
20202020-12-31	Operating cash flow	-54061000	Operating Cash Flow: -54061000 Open source
20212021-12-31	Operating cash flow	218875000	Operating Cash Flow: 218875000 Open source
20222022-12-31	Operating cash flow	-207488000	Operating Cash Flow: -207488000 Open source
20232023-12-31	Operating cash flow	-218407000	Operating Cash Flow: -218407000 Open source
20242024-12-31	Operating cash flow	-173125000	Operating Cash Flow: -173125000 Open source
20252025-12-31	Operating cash flow	-123963000	Operating Cash Flow: -123963000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -126.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-56707000	Operating Cash Flow: -48558000 Open source Capital Expenditure: 8149000 Open source
20172017-12-31	Free cash flow	-65152000	Operating Cash Flow: -57992000 Open source Capital Expenditure: 7160000 Open source
20182018-12-31	Free cash flow	91370000	Operating Cash Flow: 104648000 Open source Capital Expenditure: 13278000 Open source
20192019-12-31	Free cash flow	-119425000	Operating Cash Flow: -107705000 Open source Capital Expenditure: 11720000 Open source
20202020-12-31	Free cash flow	-80930000	Operating Cash Flow: -54061000 Open source Capital Expenditure: 26869000 Open source
20212021-12-31	Free cash flow	134700000	Operating Cash Flow: 218875000 Open source Capital Expenditure: 84175000 Open source
20222022-12-31	Free cash flow	-238212000	Operating Cash Flow: -207488000 Open source Capital Expenditure: 30724000 Open source
20232023-12-31	Free cash flow	-228367000	Operating Cash Flow: -218407000 Open source Capital Expenditure: 9960000 Open source
20242024-12-31	Free cash flow	-175561000	Operating Cash Flow: -173125000 Open source Capital Expenditure: 2436000 Open source
20252025-12-31	Free cash flow	-126377000	Operating Cash Flow: -123963000 Open source Capital Expenditure: 2414000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

77.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	6.4%	Total Liabilities: 10995000 Open source Total Assets: 172732000 Open source
20172017-12-31	Liabilities / assets	7.9%	Total Liabilities: 15648000 Open source Total Assets: 198677000 Open source
20182018-12-31	Liabilities / assets	6.4%	Total Liabilities: 34966000 Open source Total Assets: 543814000 Open source
20192019-12-31	Liabilities / assets	9.6%	Total Liabilities: 47711000 Open source Total Assets: 497908000 Open source
20202020-12-31	Liabilities / assets	46.7%	Total Liabilities: 330411000 Open source Total Assets: 708164000 Open source
20212021-12-31	Liabilities / assets	31.4%	Total Liabilities: 349606000 Open source Total Assets: 1113904000 Open source
20222022-12-31	Liabilities / assets	38.1%	Total Liabilities: 317073000 Open source Total Assets: 833268000 Open source
20232023-12-31	Liabilities / assets	45.7%	Total Liabilities: 262228000 Open source Total Assets: 573970000 Open source
20242024-12-31	Liabilities / assets	44.3%	Total Liabilities: 206338000 Open source Total Assets: 465989000 Open source
20252025-12-31	Liabilities / assets	77.3%	Total Liabilities: 350299000 Open source Total Assets: 453032000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.38× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	9.66×	Current Assets: 93371000 Open source Current Liabilities: 9669000 Open source
20172017-12-31	Current assets / current liabilities	11.64×	Current Assets: 167997000 Open source Current Liabilities: 14437000 Open source
20182018-12-31	Current assets / current liabilities	15.24×	Current Assets: 337913000 Open source Current Liabilities: 22176000 Open source
20192019-12-31	Current assets / current liabilities	10.25×	Current Assets: 345032000 Open source Current Liabilities: 33676000 Open source
20202020-12-31	Current assets / current liabilities	6.52×	Current Assets: 531197000 Open source Current Liabilities: 81447000 Open source
20212021-12-31	Current assets / current liabilities	3.98×	Current Assets: 518826000 Open source Current Liabilities: 130472000 Open source
20222022-12-31	Current assets / current liabilities	3.19×	Current Assets: 415976000 Open source Current Liabilities: 130434000 Open source
20232023-12-31	Current assets / current liabilities	2.57×	Current Assets: 334971000 Open source Current Liabilities: 130272000 Open source
20242024-12-31	Current assets / current liabilities	2.69×	Current Assets: 278001000 Open source Current Liabilities: 103194000 Open source
20252025-12-31	Current assets / current liabilities	2.38×	Current Assets: 281281000 Open source Current Liabilities: 118095000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 62.97 million Exact value Exact value: -62967000 USD 2016-01-01 – 2016-12-31: -62967000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2016-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -62967000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62967000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459019004920/rgnx-20181231.xml#193491 Filing: 000156459019004920 The citation records this snapshot. The page link may show a newer release later.	−USD 48.56 million Exact value Exact value: -48558000 USD 2016-01-01 – 2016-12-31: -48558000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2016-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -48558000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48558000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459019004920/rgnx-20181231.xml#224088 Filing: 000156459019004920 The citation records this snapshot. The page link may show a newer release later.	USD 8.15 million Exact value Exact value: 8149000 USD 2016-01-01 – 2016-12-31: 8149000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2016-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 8149000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8149000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459019004920/rgnx-20181231.xml#226470 Filing: 000156459019004920 The citation records this snapshot. The page link may show a newer release later.	−USD 56.71 million Calculation and evidence -48558000 − 8149000 USD Exact free cash flow: -56707000 USD 2016-01-01 – 2016-12-31: -48558000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 8149000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2016-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -56707000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48558000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459019004920/rgnx-20181231.xml#224088 Filing: 000156459019004920 Input fundies:CapitalExpenditure: 8149000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459019004920/rgnx-20181231.xml#226470 Filing: 000156459019004920 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 73.17 million Exact value Exact value: -73169000 USD 2017-01-01 – 2017-12-31: -73169000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2017-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -73169000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73169000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459020006826/rgnx-10k_20191231.htm#2392200 Filing: 000156459020006826 The citation records this snapshot. The page link may show a newer release later.	−USD 57.99 million Exact value Exact value: -57992000 USD 2017-01-01 – 2017-12-31: -57992000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2017-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -57992000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57992000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459020006826/rgnx-10k_20191231.htm#2729115 Filing: 000156459020006826 The citation records this snapshot. The page link may show a newer release later.	USD 7.16 million Exact value Exact value: 7160000 USD 2017-01-01 – 2017-12-31: 7160000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2017-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 7160000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7160000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459020006826/rgnx-10k_20191231.htm#2757431 Filing: 000156459020006826 The citation records this snapshot. The page link may show a newer release later.	−USD 65.15 million Calculation and evidence -57992000 − 7160000 USD Exact free cash flow: -65152000 USD 2017-01-01 – 2017-12-31: -57992000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 7160000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2017-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -65152000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57992000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459020006826/rgnx-10k_20191231.htm#2729115 Filing: 000156459020006826 Input fundies:CapitalExpenditure: 7160000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459020006826/rgnx-10k_20191231.htm#2757431 Filing: 000156459020006826 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 99.94 million Exact value Exact value: 99937000 USD 2018-01-01 – 2018-12-31: 99937000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2018-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: 99937000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 99937000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459021009855/rgnx-10k_20201231.htm#2510335 Filing: 000156459021009855 The citation records this snapshot. The page link may show a newer release later.	USD 104.65 million Exact value Exact value: 104648000 USD 2018-01-01 – 2018-12-31: 104648000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2018-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: 104648000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 104648000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459021009855/rgnx-10k_20201231.htm#2826027 Filing: 000156459021009855 The citation records this snapshot. The page link may show a newer release later.	USD 13.28 million Exact value Exact value: 13278000 USD 2018-01-01 – 2018-12-31: 13278000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2018-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 13278000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13278000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459021009855/rgnx-10k_20201231.htm#2859712 Filing: 000156459021009855 The citation records this snapshot. The page link may show a newer release later.	USD 91.37 million Calculation and evidence 104648000 − 13278000 USD Exact free cash flow: 91370000 USD 2018-01-01 – 2018-12-31: 104648000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 13278000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2018-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: 91370000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 104648000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459021009855/rgnx-10k_20201231.htm#2826027 Filing: 000156459021009855 Input fundies:CapitalExpenditure: 13278000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459021009855/rgnx-10k_20201231.htm#2859712 Filing: 000156459021009855 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 94.73 million Exact value Exact value: -94733000 USD 2019-01-01 – 2019-12-31: -94733000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2019-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -94733000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -94733000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008055/rgnx-10k_20211231.htm#2227215 Filing: 000156459022008055 The citation records this snapshot. The page link may show a newer release later.	−USD 107.71 million Exact value Exact value: -107705000 USD 2019-01-01 – 2019-12-31: -107705000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2019-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -107705000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -107705000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008055/rgnx-10k_20211231.htm#2518442 Filing: 000156459022008055 The citation records this snapshot. The page link may show a newer release later.	USD 11.72 million Exact value Exact value: 11720000 USD 2019-01-01 – 2019-12-31: 11720000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2019-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 11720000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11720000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008055/rgnx-10k_20211231.htm#2552354 Filing: 000156459022008055 The citation records this snapshot. The page link may show a newer release later.	−USD 119.43 million Calculation and evidence -107705000 − 11720000 USD Exact free cash flow: -119425000 USD 2019-01-01 – 2019-12-31: -107705000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 11720000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2019-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -119425000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -107705000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008055/rgnx-10k_20211231.htm#2518442 Filing: 000156459022008055 Input fundies:CapitalExpenditure: 11720000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008055/rgnx-10k_20211231.htm#2552354 Filing: 000156459022008055 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 111.25 million Exact value Exact value: -111250000 USD 2020-01-01 – 2020-12-31: -111250000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2020-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -111250000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -111250000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005085/rgnx-20221231.htm#2231702 Filing: 000095017023005085 The citation records this snapshot. The page link may show a newer release later.	−USD 54.06 million Exact value Exact value: -54061000 USD 2020-01-01 – 2020-12-31: -54061000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2020-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -54061000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54061000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005085/rgnx-20221231.htm#2561457 Filing: 000095017023005085 The citation records this snapshot. The page link may show a newer release later.	USD 26.87 million Exact value Exact value: 26869000 USD 2020-01-01 – 2020-12-31: 26869000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2020-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 26869000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26869000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005085/rgnx-20221231.htm#2598652 Filing: 000095017023005085 The citation records this snapshot. The page link may show a newer release later.	−USD 80.93 million Calculation and evidence -54061000 − 26869000 USD Exact free cash flow: -80930000 USD 2020-01-01 – 2020-12-31: -54061000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 26869000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2020-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -80930000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54061000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005085/rgnx-20221231.htm#2561457 Filing: 000095017023005085 Input fundies:CapitalExpenditure: 26869000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005085/rgnx-20221231.htm#2598652 Filing: 000095017023005085 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 127.84 million Exact value Exact value: 127840000 USD 2021-01-01 – 2021-12-31: 127840000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2021-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: 127840000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 127840000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017024021161/rgnx-20231231.htm#1714920 Filing: 000095017024021161 The citation records this snapshot. The page link may show a newer release later.	USD 218.88 million Exact value Exact value: 218875000 USD 2021-01-01 – 2021-12-31: 218875000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2021-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: 218875000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 218875000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017024021161/rgnx-20231231.htm#1924156 Filing: 000095017024021161 The citation records this snapshot. The page link may show a newer release later.	USD 84.18 million Exact value Exact value: 84175000 USD 2021-01-01 – 2021-12-31: 84175000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2021-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 84175000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 84175000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017024021161/rgnx-20231231.htm#1943851 Filing: 000095017024021161 The citation records this snapshot. The page link may show a newer release later.	USD 134.7 million Calculation and evidence 218875000 − 84175000 USD Exact free cash flow: 134700000 USD 2021-01-01 – 2021-12-31: 218875000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 84175000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2021-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: 134700000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 218875000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017024021161/rgnx-20231231.htm#1924156 Filing: 000095017024021161 Input fundies:CapitalExpenditure: 84175000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017024021161/rgnx-20231231.htm#1943851 Filing: 000095017024021161 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 280.32 million Exact value Exact value: -280321000 USD 2022-01-01 – 2022-12-31: -280321000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2022-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -280321000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -280321000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#4100084 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.	−USD 207.49 million Exact value Exact value: -207488000 USD 2022-01-01 – 2022-12-31: -207488000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2022-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -207488000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -207488000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2239957 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.	USD 30.72 million Exact value Exact value: 30724000 USD 2022-01-01 – 2022-12-31: 30724000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2022-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 30724000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 30724000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2264551 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.	−USD 238.21 million Calculation and evidence -207488000 − 30724000 USD Exact free cash flow: -238212000 USD 2022-01-01 – 2022-12-31: -207488000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 30724000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2022-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -238212000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -207488000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2239957 Filing: 000095017025038770 Input fundies:CapitalExpenditure: 30724000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2264551 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 263.49 million Exact value Exact value: -263494000 USD 2023-01-01 – 2023-12-31: -263494000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2023-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -263494000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -263494000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#4098346 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.	−USD 218.41 million Exact value Exact value: -218407000 USD 2023-01-01 – 2023-12-31: -218407000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2023-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -218407000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -218407000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2238281 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.	USD 9.96 million Exact value Exact value: 9960000 USD 2023-01-01 – 2023-12-31: 9960000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2023-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 9960000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9960000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2262782 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.	−USD 228.37 million Calculation and evidence -218407000 − 9960000 USD Exact free cash flow: -228367000 USD 2023-01-01 – 2023-12-31: -218407000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 9960000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2023-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -228367000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -218407000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2238281 Filing: 000095017025038770 Input fundies:CapitalExpenditure: 9960000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000095017025038770/rgnx-20241231.htm#2262782 Filing: 000095017025038770 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 227.1 million Exact value Exact value: -227102000 USD 2024-01-01 – 2024-12-31: -227102000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2024-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -227102000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -227102000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#4137940 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.	−USD 173.13 million Exact value Exact value: -173125000 USD 2024-01-01 – 2024-12-31: -173125000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2024-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -173125000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -173125000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2142296 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.	USD 2.44 million Exact value Exact value: 2436000 USD 2024-01-01 – 2024-12-31: 2436000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2024-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 2436000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2436000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2160592 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.	−USD 175.56 million Calculation and evidence -173125000 − 2436000 USD Exact free cash flow: -175561000 USD 2024-01-01 – 2024-12-31: -173125000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 2436000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2024-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -175561000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -173125000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2142296 Filing: 000119312526094013 Input fundies:CapitalExpenditure: 2436000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2160592 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 193.88 million Exact value Exact value: -193878000 USD 2025-01-01 – 2025-12-31: -193878000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Net Income: -193878000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -193878000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#4136082 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.	−USD 123.96 million Exact value Exact value: -123963000 USD 2025-01-01 – 2025-12-31: -123963000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Operating Cash Flow: -123963000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -123963000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2140516 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.	USD 2.41 million Exact value Exact value: 2414000 USD 2025-01-01 – 2025-12-31: 2414000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Capital Expenditure: 2414000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2414000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2158719 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.	−USD 126.38 million Calculation and evidence -123963000 − 2414000 USD Exact free cash flow: -126377000 USD 2025-01-01 – 2025-12-31: -123963000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2414000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REGENXBIO Inc. · 2025-12-31 REGENXBIO Inc. (edgar:1590877) Free cash flow: -126377000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -123963000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2140516 Filing: 000119312526094013 Input fundies:CapitalExpenditure: 2414000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm#2158719 Filing: 000119312526094013 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

118 filings · 3,372 latest values · 3,372 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001590877, 1590877, RGNX, edgar:1590877

Also known as REGENXBIO Inc., ReGenX Biosciences, LLC

REGENXBIO Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation